Brilinta

Brilinta, also known by its generic name ticagrelor, is a medication used to prevent blood clots. It belongs to a class of drugs called P2Y12 inhibitors. Brilinta is primarily prescribed to patients who have experienced a heart attack or have unstable angina. Its main purpose is to reduce the risk of further cardiovascular events such as another heart attack, stroke, or death from heart-related causes.

The mechanism of action for Brilinta involves blocking a specific receptor on platelets, which are blood cells responsible for clot formation. By inhibiting this receptor, ticagrelor makes platelets less likely to stick together and form dangerous clots. This is crucial in managing conditions where plaque in arteries has ruptured, leading to clot formation and potentially blocking blood flow to the heart or brain.

Brilinta is typically taken orally, usually twice a day. It is often prescribed in combination with aspirin, although the dose of aspirin may be lower than typically used for pain relief. Patients should take Brilinta exactly as prescribed by their doctor and not stop taking it without medical advice, as this can increase the risk of a heart attack.

Like all medications, Brilinta can have side effects. Common side effects may include bleeding, shortness of breath, and bruising. Serious bleeding events, although less common, can occur and require immediate medical attention. It is important for patients to discuss any concerns or pre-existing conditions, such as bleeding disorders, with their healthcare provider before starting Brilinta.